ArticleAntimicrobial agents and chemotherapy2020
Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 57 citations in OpenAlex.
- Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida.Open forum infectious diseases · 2026Article
- Clinical features of nontuberculous mycobacteria and diagnosis with nanopore targeted sequencing: a retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- Chemoproteomic Elucidation of β-Lactam Drug Targets inACS infectious diseases · 2026Article
- Optimizing target inactivation to treat multidrug-resistantAntimicrobial agents and chemotherapy · 2026Article
- Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens forAntimicrobial agents and chemotherapy · 2026Article
- Synergistic activity of dual β-lactams againstMicrobiology spectrum · 2026Article
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease.The Journal of antimicrobial chemotherapy · 2026Article
- In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.The Journal of antimicrobial chemotherapy · 2026Article
- Single-domain antibodies as potent inhibitors of clinically relevantFrontiers in microbiology · 2026Article
- Response to "The promise and pitfalls: interpreting dual β-lactam success inASM case reports · 2026Article
- Oral β-lactam combinations are effectiveMicrobiology spectrum · 2025Article
- Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect againstMicrobiology spectrum · 2025Article
- Combinations comprising dual β-lactams and a β-lactamase inhibitor achieve optimal synergistic inhibition ofAntimicrobial agents and chemotherapy · 2025Article
- Case report of peritoneal dialysis-associated peritonitis caused byASM case reports · 2025Article
- Article
- Successful treatment of macrolide-resistantASM case reports · 2025Article
- Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens forbioRxiv : the preprint server for biology · 2025Article
- Novel C5α-substituted carbapenems enhanceAntimicrobial agents and chemotherapy · 2025Article
- The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination againstAntimicrobial agents and chemotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Khalid M Dousa *Division of Infectious Diseases & HIV Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0003-3272-7231
Sebastian G Kurz *Mount Sinai National Jewish Health Respiratory Institute, New York, New York, USA.
Magdalena A TaracilaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Tracey BonfieldDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Christopher R BethelResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Melissa D BarnesResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Suresh SelvarajuDepartment of Microbiology, MetroHealth Medical Center, Cleveland, Ohio, USA.
Ayman M AbdelhamedDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
W Henry BoomDivision of Infectious Diseases & HIV Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Shannon H KasperbauerDivision of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA.
Charles L DaleyDivision of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA robert.bonomo@va.gov.
Louis Stokes Cleveland VA Medical Center · USNational Jewish Health · USUniversity Hospitals of Cleveland · USUniversity School · USGeriatric Research Education and Clinical Center · USHackensack Meridian Health · USMetroHealth · US
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MDissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complexR01AI141805 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI BARRY Neal KREISWIRTH · 2019 to 2026
$5.1MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI141805
Abstract
PubMed holds no abstract for this paper.
Indexed as
Mycobacterium abscessusPeptidyl TransferasesAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCarboxypeptidasesCeftarolineCephalosporinsImipenemMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCarboxypeptidasesCeftarolineCephalosporinsImipenemPeptidyl Transferasesantibiotic resistanceantibioticsbacteriaceftarolinediazabicyclooctaneimipeneminhibitormycobacteriaMycobacterium abscessus
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.